The Latest Cardiac and Vascular News
– NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 – ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were presented at the virtual […]
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of NEXLETOL® (bempedoic acid) Tablets and the never-ending patient cycle of diet, exercise and a statin treatment without ever […]
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formulary Coverage – – Consistently High Month-Over-Month […]
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medical Association (JAMA) Cardiology. The four Phase 3 clinical studies […]
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers – – Launch Date Accelerated by One Month at Health Care Providers Request […]
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in Europe NEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March 30th NEXLIZET™ (bempedoic acid and ezetimibe) Tablets Commercially Available in the U.S. on June 4th Strong Capital […]
– NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins – – First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved – – Esperion’s Second Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. Following NEXLETOL™ (bempedoic acid) Tablet Approval on February 21, […]
– Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism – – Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 Fixed Dose Combination Tablet LDL-Cholesterol Lowering Program – – European Commission Decision on the Marketing Authorisation Application […]
– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial – – Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment in the CLEAR […]
ANN ARBOR, Mich., April 01, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) announced today that results from the 345 patient, 24-week, Phase 3, double-blind, placebo-controlled study of bempedoic acid (CLEAR Serenity, also known as Study 3) were published today in the Journal of the American Heart Association (JAHA). Bempedoic acid is being […]
